Quantitative analysis of corticotropin-releasing factor and arginine vasopressin mRNA in the hypothalamus during chronic morphine treatment in rats: an in situ hybridization study.
The content of corticotropin-releasing factor (CRF) and arginine vasopressin (AVP) in the hypothalamic paraventricular nucleus (PVN) increases during chronic morphine treatment. Because these experiments cannot distinguish between increased synthesis or reduced release, the present study measured changes in CRF and AVP mRNAs in the PVN by in situ hybridization. Concomitantly, changes in noradrenaline turnover in the PVN and changes in plasma corticosterone release were determined. Male rats were implanted with placebo (naive) or morphine pellets for 7 days. On day 7, groups of rats received an acute injection of either saline i.p. or morphine (30 mg/kg, i.p.). Acute morphine injection did not change the total size of the labelled area for CRF mRNA in the PVN of naive or morphine-pelleted rats, indicating that the number of CRF-containing neurones was unchanged. On the other hand, in rats chronically treated with morphine, the intensity of labelling for CRF mRNA was significantly reduced, suggesting a decrease in the synthesis of CRF. In placebo rats, injection of saline or morphine did not affect the surface hybridized for AVP mRNA. By contrast, in the morphine-group injected with saline, there was a significant reduction in the number of labelled neurones, measured by the size of labelled area. Similarly, there was a decrease in intensity of AVP mRNA expression in the parvocellular and magnocellular neurones of the PVN in the morphine-group injected with saline, suggesting a decreased synthesis of AVP in these neurones. In parallel with the decrease in the expression of CRF and AVP mRNAs in the PVN, there was a pronounced decrease in noradrenaline turnover and in the release of corticosterone in the morphine-pelleted rats. In conclusion, present results show that, in addition to modifications in corticosterone secretion and in noradrenaline turnover, chronic morphine administration produces a reduction in the synthesis of CRF and AVP.
Laorden
M L
ML
Department of Pharmacology, University School of Medicine, Campus de Espinardo, 30100 Murcia, Spain. laorden@um.es
Milanés
M V
MV
Angel
E
E
Tankosic
P
P
Burlet
A
A
D000818:Animals; D001127:Arginine Vasopressin / Q000032:analysis / Q000378:metabolism*; D001835:Body Weight / Q000187:drug effects; D003345:Corticosterone / Q000097:blood; D003346:Corticotropin-Releasing Hormone / Q000032:analysis / Q000378:metabolism*; D004334:Drug Administration Schedule; D015870:Gene Expression / Q000187:drug effects; D007030:Hypothalamo-Hypophyseal System / Q000187:drug effects / Q000378:metabolism; D007031:Hypothalamus / Q000737:chemistry* / Q000187:drug effects / Q000378:metabolism; D017403:In Situ Hybridization; D008297:Male; D008734:Methoxyhydroxyphenylglycol / Q000032:analysis / Q000378:metabolism; D009020:Morphine / Q000008:administration & dosage*; D009294:Narcotics / Q000494:pharmacology; D009638:Norepinephrine / Q000032:analysis / Q000378:metabolism; D010286:Paraventricular Hypothalamic Nucleus / Q000737:chemistry / Q000187:drug effects / Q000378:metabolism; D010913:Pituitary-Adrenal System / Q000378:metabolism; D012333:RNA, Messenger / Q000032:analysis / Q000187:drug effects*; D051381:Rats; D017207:Rats, Sprague-Dawley
D009294:Narcotics; D012333:RNA, Messenger; D001127:Arginine Vasopressin; D008734:Methoxyhydroxyphenylglycol; D009020:Morphine; D003346:Corticotropin-Releasing Hormone; D003345:Corticosterone; D009638:Norepinephrine